- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03838250
Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC
A Phase I, Open-Label, Single-Dose Study to Evaluate the Safety and Efficacy of Hepatic Artery Injection of Autologous Human Bone Marrow-Derived Mesenchymal Stem Cells (Cellgram™) in Patients With Alcoholic Liver Cirrhosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After providing written informed consent, subjects will return to the study center for further evaluation and to have their Bone marrow harvested by an experienced hematologist or interventional radiologist.
Within approximately 1 month (30 ± 7 days) after Bone marrow aspiration, study participants will be admitted to the study center on Day 1.
At the study center, the participant will undergo hepatic artery catheterization by an interventional radiologist who will inject a single dose of Cellgram™. Participants will remain as in-patients and be observed for 24 hours post-infusion. Following discharge, participants will periodically return to the study center for study assessment visits over a period of 1 year.
When a suitable candidate is identified by the Investigator, the Investigator or designated healthcare professional will ask the patient about his/her willingness to be included in the clinical study. Following this, patients will be allowed sufficient time, in their own opinion, to consider study entry, and will be offered the opportunity to ask any further questions prior to signing the informed consent form.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: JIYEOUN JEONG, CCRP, Bachelor
- Phone Number: 82-02-3496-0134
- Email: jyjeong@pharmicell.com
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Recruiting
- University of Utah
-
Contact:
- Juan Gallegos-Orozco, Ph.D
- Phone Number: 801-581-7878
- Email: juan.gallegos@hsc.utah.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Alcoholic liver cirrhosis as diagnosed by clinical, biochemical, radiological, or histological evidence.
- Male or female, 18 to 70 years of age, inclusive.
- Child-Pugh class B (7 to 9 points)
- Capable, in the Investigators opinion, of undergoing hepatic artery catheterization.
- No consumption of alcohol or other potentially hepatotoxic substances considered clinically relevant in the opinion of the Investigator, within 6 months prior to screening and throughout the study.
- Provision of informed consent by the patient (or their legal representative) to participate in the clinical study.
- Able, in the Investigator's opinion, to comply with the requirements of the protocol (including the follow-up period).
- Females of childbearing potential must test negative on standard urine pregnancy test and must be willing to practice appropriate contraceptive methods for the duration of the study. Highly effective methods of birth control include hormonal birth control, intrauterine devices (IUDs), or any double-barrier method (sponges, female condoms) used by the woman in addition to contraception used by their male partner such as vasectomy or condom supplemented with spermicide.
Exclusion Criteria:
- Current diagnosis of malignant hematologic disease (e.g., acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma).
- Etiology other than alcohol for underlying liver cirrhosis.
- Baseline creatinine >1.7 mg/dL and/or estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2
Clinical history of a solid cancer within 5 years prior to screening or current diagnosis of a solid cancer (including hepatocellular carcinoma assessed by ultrasonography and elevated AFP level) and currently receiving cancer treatment.
Continuous use of a clinically relevant amount of steroids or antibiotics within 1 month prior to screening. Clinical relevance will be determined by the Investigator.
- Model for End-Stage Liver Disease score >20.
- International normalized ratio >3.0 and/or platelet counts <30,000/mm3
- Major operation within 3 months prior to screening.
- Presence of extrahepatic biliary stricture.
- Participant has undergone transjugular intrahepatic portosystemic shunt.
- Active hepatic artery or portal vein thrombosis.
- Presence of advanced hepatic encephalopathy Stages 3-4 (West Haven criteria) at the time of screening.
- Active variceal bleeding during the last 6 months before screening.
- Severe cardiac, renal, or respiratory failure.
- Positive serological test results for human immunodeficiency virus (HIV), HCV, hepatitis B surface antigen (HBsAg) and/or syphilis.
- Patient is pregnant or breast feeding, or planning to become pregnant while enrolled in the study, up to the EOS visit.
- Positive urine pregnancy test at Screening.
- Drug abuse within the past 2 years (as confirmed by patient disclosure or a urine drug screen conducted at Screening).
- Participation in an interventional clinical study within 30 days prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cellgram™ (Bone marrow-derived MSCs)
Infusion Cellgram™(Bone marrow-derived MSCs).
Single dose administration of approximately 5 x 10^7 cells/10 mL (range: 4.5 x 10^7 to 5.5 x 10^7 cells/10 mL) via the hepatic artery.
|
Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia.
Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Serious Adverse Events
Time Frame: 12 months
|
An SAE suggests a significant hazard, contraindication, side-effect, or precaution. With respect to human clinical experience, this includes any event that:
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with Hepatocellular carcinoma (primary liver cancer) development
Time Frame: 12 months
|
assessed via ultrasonography and alpha fetoprotein [AFP] analysis
|
12 months
|
Incidence of Adverse Events
Time Frame: 12 months
|
Incidence of Adverse Events as assessed by vital signs, physical examination, safety laboratory tests, and patient reporting
|
12 months
|
Liver stiffness measurement
Time Frame: 12 months
|
with transient elastography (i.e., FibroScan®)
|
12 months
|
How well the Liver is functioning
Time Frame: 12 months
|
by tests including: serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, albumin, gamma glutamyl transpeptidase (GGT) and creatinine. Units of Measure: AST will be report in U/L. ALT will be report in U/L. GGT will be report in U/L. Bilirubin will be report in mg/dL. creatinine will be report in mg/dL. Albumin will be report in g/dL |
12 months
|
Chronic liver disease as assessed by the Child-Pugh score
Time Frame: 12 months
|
The Child-Pugh Score will be used to determine the prognosis, required strength of treatment and the necessity of liver transplantation.
The score employs 5 clinical measures of liver disease (total bilirubin, serum albumin, INR, ascites and hepatic encephalopathy).
Each parameter is scored 1 to 3, with 3 indicating the most severe derangement.
|
12 months
|
Model for End-Stage Liver Disease (MELD) Score
Time Frame: 12 months
|
MELD uses the patient's values for serum bilirubin, serum creatinine, and the INR for PT to predict survival. It is calculated according to the following formula defined by Kamath et al (2001): MELD = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43 |
12 months
|
Overall survival
Time Frame: 12 months
|
defined as the time from infusion until death from any cause during the study period.
|
12 months
|
Quality of life as assessed by 36-Item Short Form Survey (SF-36) Questionnaire
Time Frame: 12 months
|
The Short Form-36 Quality Of Life questionnaire will be recorded for each patient.
The 8 subscales of the SF-36 (Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, Mental Health) and 2 summary component measures (Physical Component Summary, Mental Component Summary) will be calculated and summarized.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Juan Gallegos-Orozco, Ph.D, University of Utah
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PMC-P-08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcoholic Liver Cirrhosis
-
Pharmicell Co., Ltd.RecruitingAlcoholic CirrhosisKorea, Republic of
-
University Hospital, MontpellierNarbonne Hospital; University Hospital, NîmesTerminatedAlcoholic Liver Disease | Alcoholic CirrhosisFrance
-
Assistance Publique - Hôpitaux de ParisCompletedAlcoholic Hepatitis | Alcoholic CirrhosisFrance
-
Pharmicell Co., Ltd.CompletedAlcoholic Liver CirrhosisKorea, Republic of
-
Stempeutics Research Pvt LtdCompletedAlcoholic Liver CirrhosisIndia
-
Yonsei UniversityUnknownAlcoholic Liver CirrhosisKorea, Republic of
-
Pharmicell Co., Ltd.CompletedAlcoholic Liver CirrhosisKorea, Republic of
-
Conatus Pharmaceuticals Inc.TerminatedLiver Diseases | Liver Cirrhosis | Liver Fibrosis | NASH Fibrosis | Decompensated Non-Alcoholic Steatohepatitis Cirrhosis | Orthotopic Liver TransplantationUnited States
-
Nantes University HospitalCompleted
-
Indiana UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Cedars-Sinai Medical...Recruiting
Clinical Trials on Cellgram™ (Bone marrow-derived MSCs)
-
Pharmicell Co., Ltd.Withdrawn
-
First Affiliated Hospital, Sun Yat-Sen UniversitySecond Affiliated Hospital of Guangzhou Medical UniversityUnknownKidney Transplantation | Acute Kidney Tubular NecrosisChina
-
The University of Texas Health Science Center,...CompletedParkinson's DiseaseUnited States
-
The University of QueenslandIsopogen; Cell and Tissue TherapiesCompletedChronic Lung Allograft Dysfunction (CLAD)Australia
-
Pharmicell Co., Ltd.RecruitingErectile DysfunctionKorea, Republic of
-
The Cleveland ClinicCase Western Reserve UniversityWithdrawnInflammatory Bowel Diseases | Crohn's Disease | Pouchitis | Ulcerative Colitis Chronic | Pouch, IlealUnited States
-
Emory UniversityNot yet recruitingOsteogenesis Imperfecta | Osteogenesis Imperfecta Type III
-
Mayo ClinicCompletedConnective Tissue Diseases | Interstitial Lung DiseaseUnited States
-
Instituto de Investigación Hospital Universitario...Instituto de Salud Carlos III; Universidad Carlos III Madrid (TERMeG); St John... and other collaboratorsUnknownEpidermolysis Bullosa Dystrophica, RecessiveSpain
-
National University of MalaysiaCytopeutics Sdn. Bhd.UnknownIschemic Dilated CardiomyopathyMalaysia